Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma First development-stage asset to be added to the Essential Pharma...
Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd.
Press Release Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children™s Research Hospital for the treatment of High-Risk Neuroblastoma ...
Renaissance Lakewood, LLC completed the installation and qualification of a new high-speed nasal spray assembly line capable of assembling and packaging unit-dose and bi-dose nasal spray devices at speeds of up to 200 units per minute.
With biologics dominating headlines, one might be tempted to think that small molecule discovery is fading, or that there is little viable target and drug space left uncovered. This simply isn’t the case. In fact, small molecule drug discovery is entering a renaissance.
Renaissance Ssa's Generic Naloxone Hydrochloride Receives Approval in US
Renaissance Ssa 's Generic Dicyclomine Hydrochloride Receives Approval in US
Renaissance Ssa Llc's Generic Neostigmine Methylsulfate Receives Approval in US
Renaissance’s Generic Sodium Nitroprusside Receives Approval In US
Renaissance’s Generic Succinylcholine Chloride Receives Approval In US